Droplex BRAF Mutation Test v2
Detection of the 2 defined mutations within the proto-oncogene BRAF
Features
Thyroid cancer is the most common malignant tumor that occurs in the endocrine system and occurs at a younger age than other malignancies. Papillary Thyroid Carcinoma (PTC) accounts for about 80 % of all thyroid cancers and is characterized by spreading along the lymphatic system. About 30 ~ 60 % of PTC patients have a BRAF mutation, which is found in codon 600. Melanoma, Non-small Cell Lung Cancer (NSCLC) and Colorectal Cancer patients also are guided to screen BRAF mutation for targeted therapy. The CE-IVD certified Droplex BRAF Mutation Test v2 detects 2 defined mutations within the proto-oncogene BRAF using Digital DropletTM Technology. This assay is an in-vitro diagnostic for PTC and is additionally a companion diagnostic which helps identify Melanoma patients who are eligible for tailored treatment.
BIOTYPE is the exclusive distributor of the Droplex Test Series in Germany. Legal manufacturer of the kits is GENCURIX, Inc.
Biomarkers
Exon 15: V600E
Product specifications
- Cat. No.
- CD011
- Cancer type
- Papillary Thyroid Cancer, Melanoma
- Regulatory status
- CE-IVD
- Compatible sample type
- DNA from FFPE tissue
- Mutation variants
- 2
- Kit size/reactions
- 24 samples/kit (1 well-reaction/sample)
- Platform
- Digital DropletTM PCR
Resources
Ordering Information
Droplex BRAF Mutation Test v2
Kit size: 24 samples/kit (1 well-reaction/sample)
Cat. No.: CD011
Status: CE-IVD
Product Request
MODAPLEX
Bench-top system for molecular multi-marker testing
